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Muscle-specific tyrosine-kinase-antibody-positive myasthenia gravis (MuSK-MG) has emerged 
as a distinct entity since 2001. This disease has been reported worldwide, but with varying rat-
es among patients with generalized acetylcholine-receptor-antibody-negative MG. MuSK-MG 
was detected in approximately 37% of generalized acetylcholine receptor antibody-negative 
MG. MuSK-MG patients were predominantly female with more prominent facial and bulbar 
involvement and more frequent crises. Disease onset tended to be earlier. Patients tended to have 
a relatively poor edrophonium response but showed prominent decrement in the repetitive nerve 
stimulation test in the facial muscles. Patients were more likely to display poor tolerance of, or 
a lack of improvement with, anticholinesterase agents. Somewhat better response was observed 
with steroids and plasma exchange. Most were managed successfully with aggressive immuno-
modulatory therapies, although a higher proportion of MuSK-MG patients had a refractory 
course when compared with other forms of generalized MG. I present here an up-to-date over-
view on MuSK-MG based on our experience at the University of Alabama at Birmingham and 
the existing literature.  J Clin Neurol 2009;5:53-64
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In 1960, Simpson suggested that myasthenia gravis (MG) 
might be an autoimmune disease.
1 This was on the basis of 
his observation that autoimmune thyroid disease, rheumatoid 
arthritis, and lupus erythematosis were found more often in 
MG patients. Sixteen years later, in 1976, the autoimmune 
mechanism of MG was firmly established when Lindstrom 
et al. showed that 85% of MG patients had measurable serum 
antibodies to human muscle acetylcholine receptors (AChRs).
2 
Twenty-five years later, another serum antibody, antibody to 
muscle-specific receptor tyrosine kinase (MuSK-Ab) was re-
ported in 70% of patients with generalized seronegative MG.
3 
In this review, up-to-date information on the clinical, electro-
physiological and laboratory features of MuSK-Ab-positive 
MG (MuSK-MG) will be presented on the basis of experience 
with 235 cases of MG at the University of Alabama at Bir-
mingham (UAB) and from the current literature (Table 1). 
 
Seronegative Myasthenia Gravis 
 
The general impression has been that there is not much dif-
ference between seropositive and seronegative MG except 
for the presence of the AChR-Ab in the serum, and therapeu-
tic approaches have been identical in the two groups. Surpris-
ingly, there have been only two fully published reports and 
one abstract supporting this view. Soliven et al. found no dif-
ference in the clinical features or therapeutic response in 25 
seronegative and 120 seropositive cases and concluded that 
the absence of serum AChR-Ab did not preclude favorable 
responses to thymectomy or plasmapheresis.
4 However, they 
found that the rate of abnormal findings in the repetitive ner-
ve stimulation (RNS) test and single-fiber electromyography 
(SFEMG) was significantly lower in seronegative MG. In an 
analysis of clinical and electrophysiological features in 38 
seronegative and 102 seropositive MG patients, Oh found that 
seronegative MG represented significantly milder forms (oc-
ular and class 1 MG) compared with seropositive MG, and 
that RNS abnormalities were significantly less common in 
seronegative MG.
5 The rate of abnormality on the SFEMG 
was not significantly different between the two groups. San-
ders et al stated in an abstract that seronegative cases repre-  
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Table 1. Clinical and laboratory features in MuSK-MG, DSN-MG, and AChR-MG Generalized MG
  MuSK-MG (n=15)  DSN-MG (n=47)  AChR-MG (n=146) 
Race; White: Afro-American: White  8 : 7  7 : 40 (p=0.0119) 27  : 119 (p=0.0109) 
Sex; F : M  12 : 3 36  : 11 64  : 82 (p<0.0075) 
Onset age: <40 :  ≥40 yrs  11 : 4 17  : 30 (p=0.0141) 45  : 101 (p=0.0010) 
Mean age±SD 32.6±13.9 46.5±15.6 (p=0029) 49.9±19.7 (p=0.0012) 
MG classificaton at presentation       
I   2  21 
Ila : IIb 2  : 6 29  : 6 48  : 19 
IIIa : IIIb 0  : 5 2  : 4 11  : 26 
Iva : Ivb 0  : 1 1  : 2 1  : 8 
V 1  1  12 
Severity: II/≥III 8  : 7 37  : 10 (p=0.061) 88  : 58  (p=0.6) 
B classification  12  12 (p<0.001) 53  (p=0.0003) 
Distribution of weakness at presentation       
Ocular weakness  14  40  143 
Facial weakness  15  22 (p=0.0001) 98  (p<0.0080) 
Bulbar weakness  14  24 (p=0.0034) 79  (p<0.0034) 
Respiratory difficulty  8  9 (p=0.002) 58 
Neck muscle weakness  12  23 (p=0.0240) 64  (p=0075) 
Limb weakness  12  41  136 
Crisis 5  6  (p=0.0265) 34 
Thymoma 0  3  36  (p<0.03)(p<0.007)† 
Edrophonium test: positive  6/10  23/27  (p=0.0984) 48/49  (p<0.0001) 
RNS test in all: abnormal  14/15  29/47  (p=0.0184) 105/136  (p<0.0308) 
ADQ 5/14  18/43  48/124 
OO abnormal  12/15  17/23 (p=0.0128) 68/115 
Tarapezius 6/13  13/39  66/112 
SFEMG: abnormal  9/12  34/44  96/126 
AChE non-responsiveness  12  9 (p<0.0001) 18  (p<0.0001) 
Treatment response       
No treatment  0  1  1 
Pyridostigmine alone  0  11  10 
Immunotherapy 15  35  (p=0.029) 135 
Pyridostigmine: improvement*  2/15  19/45 (p=0.0371) 59/143  (p=0.0346) 
Steroid improvement  8/15  10/28  56/121 
IMS improvement  5/8  9/26  35/93 
IVIGimprovement 1/9  3/12  16/48 
PE improvement  4/8  3/6  20/45 
Thymectomy 7  13  59 
PR 1  2  7 
MM 1  3  18 
Long-term outcome‡  (n=11)  (n=23)  (n=74) 
Improved (I)* 7  15  48 
Minimally improved (MI) 2  1  15 
Unchanged (U) 0  7  13 
Death 1  3  10 
Remission and MM  3  8  41 
PR 1  2  15 
CSR 0  1  5 
MM 2  8  27 
*Good or excellent responses, †Compared with DSN-MG, ‡Follow-up period:  ≥3 yr. Mean Follow-up period: 10.6±8.0 yr in MuSK-MG, 
8.5±5.5 yr in DSN-MG. 9.8±5.9 yr in AChR-MG. CSR: complete stable remission, IMS: immunosuppressive therapy MM: minimal manifes-
tation, PE: plasma exchange, PR: pharmacological resmission.    
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sent milder MG restricted to the ocular muscles.
6 Thus, these 
studies supported the general impression that, though AChR-
Ab was not found, seronegative MG represented a milder 
form of autoimmune MG. Mossman et al. injected immuno-
globulin from seronegative patients intraperitoneally into mice 
and found significantly impaired neuromuscular transmission 
despite absent binding of antibody to AChR and a minimal 
loss of AChR.
7 This study conclusively showed that sero-
negative MG is an autoimmune disease but is immunologic-
ally and physiologically distinct from seropositive MG. How-
ever, the detection of an antibody responsible for seroneg-
ative MG was elusive until 2001, when the antibody to MuSK- 
Ab was first reported in patients with generalized seronega-
tive MG.
3 
 
MuSK and MuSK Induced 
Experimental Allergic   
Autoimmune Myasthenia Gravis 
 
MuSK, one of many receptors near the AChR (Fig. 1), is 
critical for the synaptic clustering of AChRs during fetal de-
velopment, and it remains important for the maturation and/ 
or maintenance of the adult neuromuscular synapse in post-
natal life. MuSK is activated by agrin, which is released from 
motor neurons, and induces AChR clustering at the postsyn-
aptic membrane. The pathogenic significance of MuSK-Ab in 
MuSK-MG was questioned initially because end-plate AChR 
density in patients remains well preserved.
8,9 However, recent 
studies unequivocally demonstrated that MuSK-Ab can cause 
MG. Active immunization of mice and rabbits with the extra-
cellular domain of MuSK protein led to EAMG and associ-
ated changes in neuromuscular junctions.
10,11 Passive immu-
nization of mice with IgG from MuSK MG patients induced 
EAMG and further demonstrated marked reduction of post-
synaptic AChR staining by fluorescent-alpha-bungarotoxin.
12 
EAMG mice showed weakness as well as decremental (23-
47%) response in the repetitive nerve stimulation test.
10,12 Jha 
et al.
10 also demonstrated that MuSK sera inhibit agrin-induced 
AChR aggregation and hypothesized that MG can be caused 
by blocking the agrin signaling pathway alone or in combi-
nation with other factors. According to this hypothesis, a pa-
tient’s MuSK-Ab causes synaptic impairment by blocking 
MuSK signaling in the postsynaptic membrane, producing 
MG. This hypothesis is most commonly accepted as a mech-
anism of reduced neuromuscular transmission in MuSK-MG. 
 
Pathological Studies 
 
Thymoma was not detected in most series in MuSK-MG 
patients. Thymoma was found in four patients in thymecto-
mized histology. A 5-mm thymoma was found in a patient 
with oculo-bulbar MG.
13 In Lavrnic’s series, thymoma was 
found in two of 17 thymus glands removed by thymectomy.
14 
Evoli found a small nodular thymoma in one of 17 thymec-
tomized patients.
15 Thus, thymoma appears to be exceeding-
ly rare. Thymic hyperplasia (lymphoid hyperplasia) was re-
ported in 19 (26%) of 73 cases (Table 2). In the present study, 
thymoma was not seen in any cases of MuSK-MG in contrast 
to three patients with double seronegative (DSN)-MG and 13 
cases of AChR-MG. 
In contrast to AChR- MG, the thymus gland in MuSK-MG 
is usually normal or demonstrates mild alterations. Lymphoid 
hyperplasia is seen rarely, being observed in 19 of 73 cases 
(Table 2). Two studies reported detailed thymic histology stud-
ies comparing MuSK-MG patients with AChR-MG and DSN- 
MG and with healthy controls, using morphometry with im-
munohistochemical or immunofluorescent staining.
16,17 Both 
studies emphasized the lack of a germinal center or lympho-
cytic infiltrates in MuSK-MG, in contrast to the changes typ-
ically seen in the majority of AChR-MG patients, and about 
half the DSN-MG patients had histological changes similar 
to those in AChR-MG patients. These findings indicate proba-
ble differences in the pathogenic mechanisms between MuSK- 
MG and AChR-MG, and suggest that thymectomy may not 
be of value in the MuSK-MG group but may of value in DSN- 
MG. 
Muscle biopsy usually showed non-specific atrophy. San-
ders reported non-specific atrophy in deltoid muscle biopsies 
in four patients
18 Padua found nonspecific atrophy and an in-
creased variability of fiber diameter in seven of 11 biopsied 
Normal MuSK-MG 
Acetylcholine 
Nerve terminal 
Muscle fiber 
AChR MuSK  Rapsyn  Antibody 
Fig. 1. Simplitied illustration of neuromuscular junction in normal
and MuSK-MG. MuSK-MG: muscle-specific tyrosine kinase antibody 
positive-MG.  
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patients
19 A more detailed comparison was made in muscle 
biopsy findings between six MuSK-MG and seven AChR-
MG patients by an Italian group. Myopathic changes {mini-
cores and ragged red fibers (mitochondrial aggregates)} were 
common in MuSK-MG patients, whereas fiber type grouping 
(neurogenic finding) and atrophy were more frequently found 
in AChR-MG patients.
20 Farrugia et al.
21 found significant 
muscle atrophy and fatty replacement in facial and bulbar 
muscles in MuSK-MG which were not found in AChR-MG 
patients. They also found a correlation between the duration 
of prednisone treatment and tongue atrophy with high signal 
in the MRI scan. 
Intercostal muscle biopsy from a 33-year-old man who was 
MuSK-Ab-positive with longstanding facial, bulbar, and re-
spiratory weakness showed no significant reduction in AChR 
or MuSK expression compared to control samples.
8 On elec-
tron microscopy, the structure of the nerve terminals and junc-
tional folds was well-maintained, although postsynaptic den-
sity was mildly reduced as a result of simplification of some 
endplates. Endplate e1ectrophysiologic studies did demon-
strate reduced miniature endplate potential amplitudes and 
currents, as observed in AChR- MG. Similarly, biceps mus-
cle biopsies from eight patients from Japan with MuSK-MG 
failed to show a significant reduction in AChR or alterations 
to postsynaptic morphology.
22 Immunoglobulin and comple-
ment deposition was scant in these reports.
8,22 These findings 
suggest that the pathogenic mechanism of neuromuscular trans-
mission defect in MuSK-MG is different from that in AChR-
MG and is not through complement-mediated AChR defect. 
This finding was anticipated because MuSK antibodies are 
predominantly immunoglobulin G4-subclass that does not ac-
tivate complement.
23 
 
Prevalence of Muscle-Specific 
Receptor Tyrosine Kinase-   
Myasthenia Gravis 
 
Essentially all patients included in various series from Nor-
th America, Europe, and Asia have had seronegative gene-
ralized MG, although there are three case reports of patients 
with pure ocular symptoms.
24-26 Follow-up in one case is less 
than one year, too short to establish a definite diagnosis of oc-
ular MG, and it is possible that this patient will generalize at a 
later time.
24 In the second case, the patient had ocular symp-
toms for two years and at least is qualified as ocular MG.
25 
The third patient had external ophthalmoplegia for 12 years, 
Table 2 . Prevalence and other demographic features of MuSK-MG
MuSK-Ab+rate 
Series  Location, countryt  Latitude 
MuSK-Ab/ 
SNGMG 
AChR-Ab  Female % 
Mean  
age  I  SPGMG 
Thymic 
hyperplasia 
Deymeer et al.  Istanbul, Turkey  41°N  0032/65 (49%)    072 36.30      
Padua et al.  Rome, Italy  45°N  0025/52 (48%)    084 49.50      
Evoli et al.  Rome, Italy  45°N  0037/78 (47%)    078 350.0   0/300 7/22 
Stickler et al.  Durham, USA  35°N  0020/44 (45%)  72/116 (62%)  095 270.0      
McConville et al.  Oxford, England  51°N  0027/66 (41%)    085   0/18     
Burns T et al.  Charlottesville, USA  38°N  0009/22 (41%)  126/148 (85%)*  078       
Zhou et al.  Baltimore, USA  39°N  0010/25 (40%)    070 33.50 0/13    1/60 
Sander et al.  Durham, USA  35°N  0012/32 (38%)   100  38.40 0/70    
Lavrnie et al.  Belgrade, Serbia  45°N  0017/44 (39%)  221/276 (80%)†  088 35.60     3/17 
Nemoto et al.  Chiba, Japan  35°N  0004/13 (31%)   100  330.0   0/570  
Ohta et al.  Kobe, Japan  34°N  0023/85 (27%)    078 450.0   0/272  6/23 
Lee et al.  Seoul, Korea  37°N  0004/15 (27%)   100  43.80 0/80   2/20 
Oh et al.  Birmingham, USA  34°N  0007/29 (24%)  73/102 (72%)*  071 290.0      
Oh et al.  Birmingham, USA  34°N  0015/62 (24%)  146/208 (70%)  080 32.60 0/13  0/160  
Wolfe et al.  Dallas, USA  33°N  0011/48 (23%)  203/251 (81%)*  100       
Nicks et al.  Leiden, Netherlands  52°N  0005/23 (22%)  189/253 (75%)†  077 600.0 0/30     
Huang et al.  Taipei, Taiwan  25°N  0005/44 (11%)    080 48.60      
Kostera-Pruszozyk Warsaw,  Poland  52°N  0004/46 (9%)   075 30.80   0/480 2/30 
Yeh et al.  Taipei, Taiwan  25°N  0001/26 (4%) 347/385  (90%)*          
Romi et al.  Bergen, Norway  60°N  0000/17 (0%)          
Illa et al.  Barecelona, Spain  41°N  0009/26 (38%)   89         
Total     304/830  (37%)   73.8%  38.54  0/89  0/416  19/73 
*Generalized MG, †All MG SNGMG, seronetative generalized MG.  
I, ocular MG. SPGMG: seropositive generalized MG, MuSK-MG: muscle-specific tyrosine kinase antibody positive-MG. 
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and MRI of the orbits revealed severe wasting of all extraocu-
lar muscles, except for the inferior oblique muscle.
26 If we use 
two years as the minimal observational period for the diagno-
sis of ocular MG, then MuSK-Ab was positive in at least two 
cases of ocular MG so far. MuSK-Ab was negative in all of 89 
ocular MG cases in six large series including our own.
18,23,28-31 
MuSK-Ab was negative in all 407 AChR-MG cases in five 
series including our own (Table 2).
29.31-34 The “MuSK-Ab” 
previously reported in AChR-MG by Ohta was subsequently 
found to be antibodies to alkaline phosphatase.
35,36 One ex-
ception is a Swedish study which reported a positive MuSK-
Ab in five (36%) of 14 seronegative patients and in five (14%) 
of 36 AChR-Ab positive patients.
37 Because of the atypical 
features of this study, this report was excluded from further 
analysis in this review. At UAB, MuSK-Ab was negative in 
all of 13 tested cases of ocular MG (one AChR-Ab positive) 
and in all of 16 tested AChR-Ab positive cases. 
Although 70% of patients with seronegative generalized 
MG from Oxford were found to have MuSK-Ab initially,
3 the 
frequency of MuSK-Ab in later series has ranged from 0% 
in Norway
38 to 49% in Turkey,
39 with a mean frequency of 
approximately 37% (Table 1).
40 Considering the relatively uni-
form rate of AChR-Ab positive rates in the range of 62-90% 
(mean 77%) worldwide, this vast regional or racial difference 
in the positive rate of MuSK-Ab is striking (Table 2). In Eu-
rope, MuSK-Ab rates seem to be lower in the northern lati-
tudes. However, this trend was not observed in the United Sta-
tes or Asia. The most striking racial difference was observed 
between whites and African-Americans (AA) in the United 
States. Oh et al.
41 reported a significantly higher positive rate 
(50%) of MuSK-Ab in AA compared with that (17%) in whi-
tes in Alabama, USA. This difference was also observed in 
three different institutions in the USA, confirming that this 
racial difference is genuine.
42 These data suggest that there 
are differences in the rates of positive MuSK-Ab among pa-
tients with AChR-Ab-negative generalized MG worldwide, 
perhaps reflecting a biological or genetic susceptibility factor. 
 
Demographic Characteristics 
 
A marked female predominance (74%) is widely observed 
(Table 1 and 2) in all large series including our own. In four 
reports, all patients identified have been women. Disease on-
set is significantly earlier than for other MG populations with 
a mean age of onset at 32.6 years, but it still ranges from the 
first through the seventh decade in large series. The present 
study demonstrates that there are more patients with MuSK 
MG with disease onset prior to 40 years of age than in other 
groups, but the mean age of onset between AChR-MG and 
DSN-MG groups did not differ considerably (Table 1). The 
late onset is most prominent in the AChR-MG groups. 
 
Clinical Phenotype 
 
Myasthenic weakness in MuSK-MG tends to be more se-
vere and refractory to treatment than that observed in patients 
with other forms of generalized MG.
40 An Italian series ob-
served more MuSK-MG patients than DSN-MG patients who 
were classified as severe by the MG Foundation of America 
(MGFA) clinical classifications. Pasnoor et al.
19 found III-V 
MGFA classification in 55% of 53 cases. Using the Quanti-
tative MG (QMG) scoring system, Stickler et al.
43 found maxi-
mum QMG scores to be significantly higher in 20 MuSK-MG 
patients than in 72 with AChR-MG. The present study show-
ed clearly that MuSK-MG patients have more severe forms 
of MG compared with the DSN-MG group but not with the 
AChR-MG group. 
Almost all series showed that the bulbar form of MG is 
common in MuSK-MG (Table 3). Our study and that of Dey-
meer et al.
39 showed that the “bulbar classification” is signifi-
Table 3. Frequency of bulbar MGFA classificdation, crisis, and III-V MG class in MuSK-MG
Series  Patients  Bulbar MGFA classification  Patients with MG crisis  Patients with III-V MG class  Timing of classification 
Deymeer 32    11  (34.4%)   Peak  severity 
Evoli et al.  37  18 (49%) 17  (45%) 32  (86%) Pesk  severity 
Farrugia et al.  13  11 (85%)     Peak  severity 
Huang  05  04 (80%)  04 (80%)   Peak  severity 
Nemoto et al.  04  02 (50%)  03 (75%)   Peak  severity 
Padua 25  15  (60%)     Peak  severity 
Pasnoor 53  36  (68%) 24  (45%) 29  (55%) Peak  severity 
Pruz  04  04 (100%)  02 (50%)  03 (75%) Peak  severity 
Sanders et al.  12  08 (67%)  03 (75%)  09 (75%) Peak  severity 
Zhou et al.  10  07 (70%)   08 (80%) At  diagnosis 
Wolfe et al.  21  16 (63%) 10  (48%)* 15  (71%) At  diagnosis 
*At severity.  
MGFA: Myasthenia Gravis Foundation of America, MuSK-MG: muscle-specific tyrosine kinase antibody positive-MG.    
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cantly more common compared with AChR-MG and DSN-
MG groups (Table 1 and 3). 
There is some evidence that myasthenic crisis is also more 
common (35-80%) in patients with MuSK-MG (Table 1 and 
3). Nemoto et al.
32 found this to be true in comparison with 
AChR-MG patients, whereas our study verified it only in com-
parison with DSN-MG patients. 
Attempts to relate disease severity with MuSK-Ab concen-
tration have met with varying success. However, in the largest 
analysis of 83 serum samples from 40 patients, there was a 
correlation between antibody levels and disease severity, me-
asured as a function of both clinical classification and QMG.
44 
Furthermore, in a subgroup of 14 patients measured both be-
fore and after treatment, immunosuppressive therapy signifi-
cantly reduced antibody titers. No appreciable changes were 
seen after thymectomy. Ohta also observed a good correlation 
between in the MuSK-Ab titer and QMG score in serial stud-
ies of 12 individuals.
33 
Three main patterns of generalized disease have been ob-
served in MuSK-MG, two of which may be helpful in distin-
guishing these patients from AChR-MG patients.
18,40 The most 
classical and common pattern is characterized by rapidly pro-
gressing bulbar weakness with dysphonia (nasal voice), dys-
phagia, and chewing difficulty. These patients remain the most 
severely affected throughout the course of the disease. Ocular 
symptoms (diplopia and ptosis) are usually present but mild. 
Involvement of limbs was relatively less severe and incon-
sistent. In three series, limb weakness was absent in almost 
50-68% of cases.
29,33,34 In the present series, limb weakness 
was present in 80% of patients. Facial weakness, followed 
by bulbar and ocular weakness, was observed in all patients, 
and was a distinguishing feature from AChR-MG or DSN-
MG. Respiratory difficulty was observed in one-half the pa-
tients. Profound facial and tongue atrophy has been described 
as one of the characteristic findings in MuSK-MG by the Ox-
ford group.
21 This was a common clinical feature, confirmed 
by magnetic resonance imaging, and was observed in seven 
of 15 MuSK-MG patients.
21 Padua
19 also reported tongue at-
rophy in 11 (44%) of 25 cases. This atrophy appears to be a 
feature of longstanding disease managed with chronic cor-
ticosteroids. Though profound facial and tongue atrophy is 
claimed as a unique feature of MuSK-MG, it has rarely been 
reported in other series: in only three of 17 cases in Lavric’s 
series,
14 in three of 53 cases in Pasnoor’s series,
45 and in one 
case in our series. She had had MG longer than 18 years, but 
not on steroid. 
The second pattern is notable for focal predominant neck, 
shoulder, and respiratory involvement with little or delayed 
oculo-bulbar weakness. In Sanders’ series, this was the most 
common pattern seen in seven of 12 MuSK-MG patients. Pa-
dua
34 reported one patient with neck muscle weakness, and 
Kostera-Prusczyki et al had one patient with neck weakness 
and respiratory difficulty. Spengos et al.
46 also reported a case 
of “dropped head syndrome” as a prominent clinical feature 
in MuSK-MG with thymic hyperplasia. These patients may 
present a diagnostic challenge because MG is not usually con-
sidered as a diagnostic possibility. In three cases, Stickler and 
Padua
19,43 were able to make the diagnosis of MG by SFEMG 
in cervical paraspinal muscles as the only abnormality when 
the extensor digitorum communis (EDC) and frontalis muscle 
SFEMG were normal. These cases emphasize the need for the 
SFEMG in a clinically involved muscle. The third pattern is 
indistinguishable from AChR-MG.   
Neonatal MG was reported in three infants who were born 
to MuSK-MG mothers.
45,47,48 Two had a classical transient 
neonatal MG lasting 3 weeks.
45,48 However, the other infant 
had a more prolonged recovery with residual symptoms of 
occasional swallowing difficulty, intermittent ptosis, and stri-
dor when weeping at 20 months.
47 
Unusual MuSK-MG cases included vocal cord paralysis in 
two MuSK-MG cases,
50,51 and one patient with MG and Mor-
van’s syndrome who had positive AChR, MuSK, and voltage 
gated potassium channel (VGKC) antibodies.
56 
In the present series, the clinical features are compared with 
those in two other types of MG. Clearly, the bulbar classifica-
tion is significantly common in MuSK-MG. Respiratory weak-
ness and crisis are significantly common in MuSK-MG only 
compared with DSN-MG. As for muscle strength evaluation, 
facial, bulbar and neck weakness are significantly common 
in MuSK-MG. Limb weakness is also common. Thus, the pre-
sent series is comparable with other series with regard to the 
clinical features of MuSK-MG. The second phenotype was 
not observed in the present series. Pasnoor et al. had a similar 
esxperience. 
 
Diagnostic Features 
 
Edrophonium and neostigmine tests 
Diagnostic testing with either edrophonium or neostigmine 
injection was positive in 50-70% of MuSK-Ab-positive cases 
in the large series (Table 4).
14,19,29,45,52 Two series with edro-
phonium or neostigmine injection reported a higher (70%) 
positive rate,
14-29 while two series with edrophonium alone 
reported a lower (50%) rate.
19,52 It is possible that neostig-
mine injection might have played a role in the higher posi-
tive rate by preventing cholinergic side effects with atropine, 
which is usually given with the neostigmine test. Hatanaka et 
al.
52 reported that positive edrophonium testing is significantly 
less common in the MuSK-MG group than in either the AChR- 
MG or DSN-MG group. The most striking finding with edro- 
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phonium testing in MuSK-MG is that it may worsen patients’ 
myasthenic symptoms (hypersensitivity) or precipitate nic-
otinic (intolerance) and muscarinic side effects, such as in-
creased weakness, widespread fasciculation, severe stomach 
cramping, or diarrhea. Hatanaka et al.
52 observed this in three 
of 10 cases: worsening of myasthenic symptoms (hypersen-
sitivity) in one, intolerance of edrophonium in one, and se-
vere muscarinic effect in one. Evoli et al.
29 also observed wors-
ening of myasthenic symptoms in one case and widespread 
fasciculation in ten patients. The low percentage of positive 
edrophonium testing may reflect the poor responsiveness to 
anticholinesterase treatment which has been reported in MuSK- 
MG.
53 More than 70% of MuSK-MG patients were nonres-
ponsive to anticholinesterase therapy, a significantly higher 
proportion than for other MG populations.
52 Repetitive dis-
charges of compound muscle action potential (CMAP) on 
low-frequency stimulation triggered by moderate doses of 
pyridostigmine and edrophonium 10 mg with worsening of 
myasthenic symptoms were reported in a patient with MuSK- 
MG and may be a useful indicator of poor tolerance.
54 
The present study showed a 60% positive rate on the edro-
phonium test in ten tested cases. Compared with AChR-MG 
and DSN-MG patients, MuSK-MG patients had a significant-
ly low positive rate. Among four negative cases, three devel-
oped worsening of myasthenic symptoms and one, intolerance 
with cholinergic (muscarinic) symptoms with the edropho-
nium test. 
 
Repetitive nerve stimulation 
Earlier series suggested that repetitive nerve stimulation (RNS) 
had a relatively low yield in MuSK-MG patients (Table 5).
18,29 
For instance, RNS of limb muscles was abnormal in 57% of 
patients with MuSK-MG versus 78% of DSN-MG patients.
29 
Sanders reported a decremental response in two (33%) of six 
patients.
18 Padua observed abnormal decremental response in 
the RNS test in the limb muscles only in three (12%) of 25 
MuSK-MG patients. On the contrary,
19 Oh’s study, based on 
cases at two University Centers, showed the highest diag-
nostic yield in MuSK-MG (86%) compared with AChR-MG 
(81%) or DSN-MG (55%).
55 This was mostly due to the high-
er rate of abnormality in the facial muscles and was confirmed 
by subsequent studies (Fig. 2).
43,45 The earlier series did not 
do the RNS test on the facial or trapezius muscles.
18,29 
Oh’s study also showed that percentage decrements were 
of greater magnitude in MuSK-MG patients in the facial mus-
cles than in the other two groups, but a greater abnormality 
was observed in AChR-MG group in the abductor digiti qu-
inti (ADQ) muscles.
55 Including facial muscles in RNS pro-
tocols is important when evaluating MG patients who are po-
tentially MuSK-seropositive. Facial RNS abnormalities reflect 
the propensity for cranial muscle involvement in this pop-
ulation. The present study at UAB showed the same findings 
as noted in the previous report. 
 
Single-fiber electromyography 
SFEMG provided critical information for diagnosis of many 
MuSK-MG patients in the earlier series when the RNS test 
on the limb muscles was normal (Table 6). In the MuSK-Ab-
positive series by Evoli et al.
29 SFEMG of facial muscles was 
utilized to confirm the diagnosis of MG for cases with normal 
RNS. SFEMG was abnormal in all of 16 patients who under-
went the procedure. Sanders et al. found SFEMG of the EDC 
to be normal in eight (67%) of 12 cases.
18 Investigation of the 
neck extensor muscles in two cases and the frontalis and del-
toid in one case detected abnormal jitter in three of the pa-
Table 4. Results of edrophonium test
Series  Patients  Positive  Comments 
Padua 20  10  (50%), E   
Lavrnic 17  12  (70.6%), E or N   
Evoli 37  26  (70.3%), E or N  Worsening in 2. Widespread fasciculation in 10 
Hatanaka 10  05 (50%), E  Worsening in 1; intolerance in 1; muscarinic effect in 1 
Pasnoor 32  21  (66%) E   
Present study  10  06 (60%) Worsening  in  2; Intolerance in 1 
 
ADQ 
Orb oculi 
0.2 mV 
5 mV 
-31% 
-3% 
Fig. 2. Classical repetitive nerve stimulation response in MuSK-
MG. A remarkable decremental (31%) response in the orbicularis
oculi (Orb oculi) muscle and normal response (3%) in the abductor
digiti quinti (ADQ) muscle. Low CMAP amplitude is also noted in
Orb oculi muscle. MuSK-MG: muscle-specific tyrosine kinase anti-
body positive-MG, CMAP: compound muscle action potential.  
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tients with normal EDC studies. 
In analogous fashion to RNS abnormalities, SFEMG of limb 
muscles was reported to have a relatively low yield in MuSK- 
MG (Table 6). In several studies, the percentage of MuSK-
MG patients with abnormal jitter on EDC recording was sig-
nificantly lower than for either AChR-MG or DSN-MG pa-
tients.
32,43,56,57 In the latter two populations, SFEMG of the 
EDC was abnormal at least in 80% of the time. EDC fiber pairs 
displaying abnormal jitter or blocking tended to be lower in 
MuSK-MG patients.
19 Farrugia et al.
57 found abnormal jitter in 
only two of 13 patients using the concentric needle for the 
SFEMG test on the EDC muscle, but abnormal jitter in the 
facial muscles in 66% of cases. Kuwabra et al.
55 found abnor-
mal jitter in one of three cases in the EDC using the stimula-
tion SFEMG.
56 Oh et al.
55 and Pasnoor et al.
45 however, con-
firmed abnormal jitter in the EDC in nearly all tested MuSK-
MG patients. Oh et al.
55 did not observe any obvious difference 
between MuSK-MG, AChR-MG and DSN-MG groups. The 
present study also showed 67% abnormality in the EDC mus-
cles on the SFEMG. In one patient with normal SFEMG in 
the EDC muscle, the frontalis muscle showed abnormal jitter. 
In three other cases, the facial muscles were not checked. The 
reason for this difference between our series and prior reports 
is most likely due to the frequency of involvement of limb 
muscles. Limb weakness was absent in 68% of cases in Ev-
oli’s series
29 and in 11 of 12 cases in Sanders’ series.
18 In our 
study, in contrast, limb weakness was observed in 80% of 
cases.
55 Thus, as a group, our patients had a greater degree of 
upper-limb involvement. Unlike those of Sanders et al.
18 our 
patients tended to have more generalized impairments (Table 
1) with weakness extending beyond ocular, oropharyngeal, 
neck extensor, and respiratory muscles. 
As a whole in MuSK-MG, SFEMG of more proximal mus-
cles including the deltoid, frontalis, orbicularis oculi, or neck 
extensors may be markedly abnormal in patients with normal 
EDC jitter.
18,56,57 Thus, it is important to do the SFEMG in 
the affected muscles in MuSK-MG patients if the EDC mus-
cle is normal. 
 
Needle EMG 
With conventional EMG, a myopathic pattern of small-am-
plitude, short-duration (SASD) motor unit potential (MUP) has 
been observed in three series. Padua observed SASD MUPs 
in 44% of MuSK-MG patients in contrast to 26% of DSN-
MG patients.
19 Sanders
18 reported scattered fibrillations and 
SASD MUPs in five patients. Using quantitative EMG in 
13 patients with MuSK-MG, Farrugia et al.
58 found a signifi-
cant decrease in the mean duration of MUP in MuSK-MG as 
Table 5. Abnormal rate in the repetitive nerve stimulation (RNS) test in the various muscles
Series  Patient number  Abnormal limb RNS (%)  Abnormal facial RNS (%)  Total cases 
Evoli et al.  37  21/37 (57), ADQ, deltoid    57% 
Sanders et al.  12  002/6 (33), hand & shoulder m    33% 
Padua et al.  25  03/25 (12), ADQ, deltoid    12% 
Nemoto et al.  04  001/4 (25), ADQ  002/4 (50) 50%* 
Oh et al.  14  05/10 (50), ADQ  11/13 (85) 86%  (12/14)* 
Stickler et al.  20  04/13 (31), hand & shoulder m  003/4 (75) 52%  (7/13)* 
Lavrnic et al.  17  08/17 (47)   47% 
Pasnoor et al.  53  08/32 (25) 31/39  (70) 39/47  (83%)* 
Present study  15  05/14 (36), ADQ  12/15 (80) 93%  (14/15)* 
*All three muscle testing: limb, trapezius, and facial muscle.  
ADQ: abductor digiti quinti. 
 
Table 6. Abnormal rate in SFEMG 
Series  Patient number  Abnormal rate in EDC  Abnormal rate in other muscle  Abnormal in all muscles 
Evoli  37    16*, facial m   
Sanders 12  6  ?  2†, neck m  Normal in EDC in 6 
Stickler et al.  20  11/18 (59%) 2 †, neck m   
Oh et al.  14  08/10 (80%) 1/1,  facial  m  9/10 
Farrugia et al.  13  02/13 (15%)  9/12, facial m   
Kuwabra et al.  03 1/3  2/3  3/3 
Lavrnic et al.  17  11/11?    11/11‡ 
Pasnoor et al.  53  18/21 (86%) 1/1,  facial  m  19/21  (90%) 
Present study  15  08/12 (67%) 1/1  9/12 
*Abnormal SFEMG in all cases with normal RNS test, †2 cases, SFEMG in EDC and frontalis muscles was normal, ‡Did not specify which muscle. 
SFEMG: single-fiber electromyography, EDC: extensor digitorum communis. 
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well as in AChR-MG, and a myopathic EMG pattern in 50% 
of MuSK-MG and 40% of AChR-MG patients, and conclud-
ed that the facial atrophy seen in some MuSK-MG patients is 
of myopathic origin, resulting from either musclefiber shrink-
age or loss of muscle fibers from motor units. In our study, all 
three tested patients showed SASD MUPs and two showed 
scattered fibrillation potentials.
55 One of two had peripheral 
neuropathy accounting for the fibrillation. It appears that SA-
SD MUPs are common and fibrillation not uncommon in 
MuSK-MG. Such needle EMG abnormalities are unusual for 
MG. A myopathic EMG pattern was observed in only 33-38% 
of MG cases in other series.
58,59 Fibrillation potentials were 
reported to be extremely rare in MG, but no exact figure was 
reported. 
 
Response to Treatment 
 
Anticholinesterase agents 
The clinical response to anticholinesterase agents (anti-ChE) 
in MuSK-MG has generally been unsatisfactory, with im-
provement in a minority of patients. Unresponsiveness to stan-
dard pyridostigmine dosing was reported in an early series,
18,29 
and this observation was confirmed in later reports.
14,15,52,53 
Intolerance manifested by severe muscatinic and nicotinic 
side-effects was common.
14 Worsening of myasthenic symp-
toms was also reported with anti-ChE with cholinergic crisis 
in a few patients. 
In a series of 14 patients with MuSK-MG at two United 
States (US) University Centers, only three of 14 benefited from 
pyridostigmine.
52 Anticholinesterase nonresponsiveness was 
noted in the remaining 11 patients, classified as 4 with no im-
provement, 4 intolerant as a result of cholinergic side-effect, 
and 3 hypersensitive with worsening of myasthenic symptoms. 
Nonresponsiveness to anticholinesterase agents was signifi-
cantly more common in MuSK-MG patients than in AChR-
MG or DSN-MG patients.
52 In another series, 30% of MuSK- 
MG patients responded to pyridostigmine and continued it 
long term, a lower percentage than for patients who were se-
ronegative.
28 Evoli et al.
15 in the latest review reported mild 
or no benefit in 70% of cases and a satisfactory response in 
21% of 57 cases. They observed frequent appearance of cho-
linergic side effects, and cholinergic crisis in 9% of cases. Pa-
snoor et al.
45 found that only eight (15%) of 51 patients re-
sponded to pyridostigmine, whereas 15 had intolerable side-
effects, and ten worsened. The present study showed non-re-
sponsiveness in 80% of cases and long term benefit in 13% 
of cases. Hypersensitivity to anti-AChE was noted in the RNS 
test by an extra repetitive discharge.
54 This electrophysiolo-
gical feature correlates with clinical deterioration and may be 
a useful indicator of the adverse potential of anticholinesterase 
agents in select patients. 
 
Thymectomy 
Most studies do not report clinical benefit from thymecto-
my for patients with MuSK MG (Table 7). Some centers do 
not recommend the procedure for this population, on a theoret-
ical basis in regard to thymus pathology, as discussed above.
17 
Seven patients followed for at least 8 months after surgery did 
not appear to benefit.
18 An eight-months follow-up period is 
insufficient to assess the final benefit of thymectomy. Neither 
did 17 patients in another series, most of whom remained de-
pendent on chronic immunosuppressive therapy and showed 
no better outcome than those who did not undergo surgery.
29 
Some reported remission in a few patients: four of 9 thymec-
tomized patients in Lavric’s series
14 and two of 4 thymecto-
mized patients in another series.
34,45 In the present study, one 
of five patients achieved pharmacological remission. Thus, 
these data seem to argue against performing thymectomy. 
 
Immunosuppressive therapy 
Because of the disease severity and poor response to anti-
AChE-Is, 95% to 100% of MuSK-MG patients require im-
munosuppressive treatment.
53 In contrast to anticholinesterase 
agents, MuSK-MG patients for the most part have a favorable 
Table 7. Improvement rate and rate of thymic hyperplasia
Series  Patient  Thymecomty  Improvement  Thymic hyperplasia 
Evoli et al.  37  15  None  0 
Zhou et al.  10  06   1/6  (17%) 
Lavrnie et al.  17  09 4; 2 CSR, 2 PR,  7/17 (41%), thymoma in 2 
Ohta et al.  23  23    6/23 (26%) 
Kostera-Pruszozyk  04  04 2; 1 CSR; 1 PR  2/3 (67%) 
Saunders 12 07 0*   
Nemoto  04  04   1/1 
Evoli et al.  57  17  0  1; thymoma 
Pasnoor et al.  53  18  7; 1 CSR; 3 PR   
*Followed for 8 months. No improvement.  
CSR: complete stable remission, PR: pharma cological remission.    
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response to immunosuppressive therapy (Table 8).
53 However, 
this is usually achieved with various combinations of immu-
nosuppressive agents. A variety of agents have been used, in-
cluding corticosteroids, azathioprine, cyclosporine, mycophe-
nolate mofetil, cyclophosphamide, and rituximab.
53,61-63 Zou 
et al.
28 reported that various combinations of immunosup-
pressive therapy produced improvement in virtually all pa-
tients. However, this is not a common experience by others. 
Evoli et al.
15 reported refractory disease (repeated exacerba-
tion on high-dose immunosuppressive agents) in 23% of 57 
cases. In 20% of cases, no change or minimal improvement 
was noted in the present series. Though Sanders
60 reported the 
best improvement results (89%) with mycophenolate mofetil 
among immunosuppressive (IS) agents, the general consen-
sus is that the best improvement was achieved with high-dose 
prednisone.
14,15,53 The response rates to various immunomo-
dulatory therapies from four U.S.-based series are summarized 
in Table 7. In refractory cases, highdose cyclophosphamide 
(50 mg/kg daily intravenously for four days) has been used 
safely and effectively with no symptom recurrence for 1.5 to 
3.5 years.
61,63 Similarly, rituximab was effective and well-tol-
erated in a patient who had been refractory, with disease sta-
bilization for 12 months after initiation.
62 The present study 
showed improvement (excellent or good) in 53% of patients 
with steroid and in 50% of patients with other immunosup-
pressive agents. 
 
Plasma exchange 
In uniform fashion across studies, plasma exchange has had 
a favorable effect on MuSK-MG, usually with dramatic im-
provement
15,53 and showing at least transient benefit in pa-
tients refractory to other interventions
15 In three U.S. series, 
the response rates to plasma exchange ranged from 51% to 
91% (Table 8). In the present series, plasma exchange (PE) 
brought improvement in 50% of cases. 
 
Intravenous immunoglobulin 
There seems to be some disagreement concerning the response 
rate to intravenous immunoglobulin (IVIG) in MuSK-MG 
patients. Evoli
15 reported that MuSK-MG patients responded 
well to PE and IVIG. No detailed data were available in the 
report. According to four U.S. reports, IVIG appears to be less 
effective in patients with MuSK-MG than other immunomo-
dulatory therapies, showing a favorable response in 19% and 
44% of patients (Table 8)
18,45,53 In Wolfe’s series, IVIG was 
more effective in AChR-MG than in MuSK-MG.
53 Pasnoor 
et al.
45 reported an improvement in 5 (25%) of 25 treated cases. 
Still, two Japanese women dependent on plasma exchange 
who were unresponsive to thymectomy, corticosteroids, and 
tacrolimus demonstrated both clinical and electrophysiological 
improvement three days after initiation of IV-IG.
64 The pres-
ent study showed IVIG effectiveness in one of 9 treated pa-
tients, confirming the U.S. experiences. 
 
Prognosis 
 
Though MuSK-MG is hard to treat, the general impression is 
that the outcome of MuSK-MG patients is on a par with that 
for other MG populations and that response to immunosup-
pression is similar.
28,39,45 However, the maintenance dose of 
corticosteroids in one series was significantly higher in Mu-
SK-MG patients (30 mg/48 hours) than in AChR-MG (18 mg 
for 2 days) or DSN-MG patients (10 mg for 2 days).
39 
When comparing therapeutic results in MuSK-MG and 
AChR-MG in meta-analysis, Evoli found significant differ-
ences in remission rates.
15 In patients with MuSK-MG, the 
percentage of remission ranged from 10 to 35% (mean, 22%) 
and was significantly lower than that reported in AChR-MG 
(24-58%, mean, 38%)(p=0.005). In the same study, the mean 
rates of complete stable remission (CSR) were 7.5% in MuSK- 
MG and 16% in AChR-MG (p=0.01). Pasnoor
45 reported re-
mission in six (18%) of 33 patients who were followed longer 
than three years: CSR in two and pharma cological remission 
(PR) in four (Table 9). The present study did show a sig-
nificantly higher remission rate (55%) in AChR-MG than in 
MuSK-MG (27%). However, there was no significant differ-
ence between the response in MuSK-MG versus DSN-MG 
groups. 
Table 8. Improvement rate to immunotherapy in MuSK-MG
  Wolfe et al. (n=21)  Pasnoor et al. (n=53)  Present (n=15)  Sanders (n=31) 
Prednisone 15/20  (75%) 27/51  (54%) 8/15  (53%) 15/20  (75%) 
Immunosuppressive agents  08/14 (66%) 17/38  (45%)  05/8 (63%)  
Azathioprine  04/10 (40%)  07/17 (41%)  03/7 (43%)  07/13 (54%) 
Mycophenolate mofetil  04/7 (57%)  08/17 (47%)  01/3 (33%) 17/19  (89%) 
Cyclophosphaide 1/1  01/3 (33%)  01/1 (100%)  
Others 0/2  0/2  0/1   
IVIG  03/12 (25%)  05/25 (20%)  01/9 (11%)  04/9 (44%) 
Plasma exchange  06/11 (54%) 17/33  (51%)  04/8 (50%) 21/23  (91%) 
IVIG: Intravenous immunoglobulin, MuSK-MG: muscle-specific tyrosine kinase antibody positive-MG.    
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In a preliminary report, a higher percentage of MuSK-MG 
than AChR-MG patients were resistant to immunosuppressive 
medication.
65 Furthermore, poor MGFA post-intervention sta-
tus (unchanged or worse) was observed in 22% of patients 
who were MuSK-Ab-positive, a proportion that was 1.5 to 2 
times higher than other populations, but this did not reach sta-
tistical significance.
39 With a mean follow-up period of eight 
years, Wolfe’s studies demonstrated a poor post-intervention 
status in four patients (19%), and the present study, a poor 
post-intervention status in two (20%) cases. 
An unstable clinical course in the first few years after onset 
with periodic cranial, bulbar, respiratory, and limb exacerba-
tions requiring plasma exchange was common, observed in 
approximately 30% of patients.
29 Nevertheless, with aggres-
sive therapy most MuSK-MG patients ultimately fare well. 
In larger series, including our own, at least three-fourths of 
patients are classified as improved, with minimal manifesta-
tions, or as in remission on post-intervention status.
45 However, 
remission rate is low and permanent weakness with some fa-
cial and bulbar muscles was evident in 30% of cases.
15 
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